Atossa Genetics (ATOS) to Release Quarterly Earnings on Monday

Key Points

• Atossa Genetics is set to release its Q2 earnings report on August 11th, with analysts expecting a loss of ($0.06) per share for the quarter.
• The company’s stock price recently increased slightly to $0.84 and has a market capitalization of $107.99 million.
• Analysts have recently upgraded Atossa Genetics to a “strong-buy” rating, with price objectives reaching as high as $7.50.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. On average, analysts expect Atossa Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Genetics Price Performance

Shares of NASDAQ:ATOS traded up $0.01 on Monday, reaching $0.84. 90,340 shares of the company traded hands, compared to its average volume of 884,223. Atossa Genetics has a fifty-two week low of $0.55 and a fifty-two week high of $1.66. The company's 50 day moving average is $0.85 and its 200-day moving average is $0.80. The stock has a market capitalization of $107.99 million, a PE ratio of -3.98 and a beta of 0.92.

Analyst Ratings Changes

ATOS has been the subject of a number of recent research reports. Craig Hallum upgraded Atossa Genetics to a "strong-buy" rating and set a $4.00 price objective for the company in a research report on Thursday, June 5th. Ascendiant Capital Markets increased their price objective on Atossa Genetics from $7.25 to $7.50 and gave the company a "buy" rating in a research report on Friday, June 6th.

Institutional Trading of Atossa Genetics

A hedge fund recently raised its stake in Atossa Genetics stock. Bank of America Corp DE grew its holdings in Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) by 51.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,475 shares of the company's stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Genetics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.